Phase 3 N=736 A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 8.0; 8.7; 8.8 Months — p=0.0318
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,340 Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
Mixed Hyperlipidemia
Primary: Percentage Change From Baseline in the LDL-C/HDL-C Ratio — -50.9; -53.0; -37.6; -42.4 Percentage Change — p=<0.001
Phase 3 N=32 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 29; 5 participants
Phase 3 N=135 Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
Asthma
Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…
Phase 3 N=1,218 Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Epilepsy
Primary: Number of Participants With Treatment-emergent Non-Serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs) — 1018; 288 participants
Phase 3 N=576 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
Asthma
Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 1.74; 0.93; 0.83 Number of exacerbations per year — p=<0.001
Phase 3 N=67 Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
Hyperparathyroidism, Primary · Hypercalcemia
Primary: Percentage of Participants With Mean Corrected Total Serum Calcium Concentration ≤ 10.3 mg/dL (2.57 mmol/L) During the EAP — 0.0; 75.8 percentage of participants…
Phase 3 N=239 Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis
Target Bleeding Site During Peripheral Vascular Surgery
Primary: The Primary Efficacy Endpoint is Time to Hemostasis. — 46.4; 26.3; 62.7; 31.6 percentage of subjects
Phase 3 N=319 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
Cancer
Primary: Neurotoxicity Assessment at Baseline — 8.5; 7.3; 5.23; 4.58 units on a scale
Phase 3 N=28 Drug Combination on Exercise Performance at High Altitude
Acute Mountain Sickness
Primary: Time (Minutes) to Complete 2 Miles on a Treadmill — 1544; 1540 seconds
Phase 3 N=623 A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Schizophrenia
Primary: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score — -20.9; -21.8; -9.8 units on a scale — p=<0.001
Phase 3 N=2,034 A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With…
Phase 3 N=346 Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
Idiopathic Parkinson's Disease
Primary: Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period — -1.13; -2.36 hours — p==0.0002
Phase 3 N=143 Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
Diabetes · Diabetes Mellitus, Type 2
Primary: HbA1c (Glycosylated Haemoglobin) — 7.4; 7.2 percentage of glycosylated haemoglobin
Phase 3 N=1,066 Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Lower Urinary Tract Symptoms · Benign Prostatic Hyperplasia
Primary: Number of Participants With Adverse Events (AEs) — 499; 255; 12; 69 participants